Flotufolastat ¹⁸F Other names: Flotufolastat F-18

Chemical formula: C₆₃H₉₉FN₁₂O₂₅Si  Molecular mass: 1,471.612 g/mol  PubChem compound: 166177191

Therapeutic indications

Flotufolastat ¹⁸F is indicated for:

Detection of prostate-specific membrane antigen positive lesions in patients with prostate cancer

Population group: men, only adults (18 years old or older)

Flotufolastat (18F) is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Flotufolastat ¹⁸F is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2023: POSLUMA Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈